RTOG-0837

Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed Glioblastoma

Principal Investigator

Tracy Batchelor

Status

Disease Site

Brain [BN] Other

Phase

II

Developmental Therapeutics

No

Primary Objective

To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by the 6-month progression-free survival rate.

Data Collection Notice:

Data for this trial is being collected via the NRG/RTOG Data Center.

Patient Population

Histopathologically confirmed glioblastoma (WHO Grade IV) confirmed by central review  prior to Step 2 registration. Tumor tissue that is determined by central pathology review prior to Step 2 registration to be of sufficient size for analysis of MGMT status. The tumor must have a supratentorial component.

Target Accrual

283